EGFR and breast carcinoma: Interestingly, the EGFR inhibitor 1e could significantly reduce the migratory potential of these sorted populations of breast cancer cells and CSCs treated with doxorubicin at low concentration (0.01 μM) that was comparable with high dose of Doxorubicin (0.1 μM) alone, which indicates the anti‐migratory potential of identified EGFR inhibitor 1e in the presence of chemotherapeutics.